Carmelina Dimatteo
Nurse Practitioner · Scarsdale, NYNPI 1437286689
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 496 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,111 and has fallen 54.4% since, to $1,420 in 2025. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 496 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- Lilly USA, LLC$868
- Novartis$842
- Boehringer Ingelheim$712
- Actelion Pharmaceuticals US, Inc.$598
- plus $4K from 32 others
What the payments were for
- Food & beverage$10,83399%
- Education$1021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 104 | $2,425 |
| Novo Nordisk | 55 | $1,226 |
| Lilly USA, LLC | 43 | $868 |
| Novartis | 39 | $842 |
| Boehringer Ingelheim | 34 | $712 |
| Actelion Pharmaceuticals US, Inc. | 26 | $598 |
| Esperion Therapeutics, Inc. | 20 | $541 |
| Merck | 22 | $490 |
| Amgen | 18 | $385 |
| AstraZeneca | 18 | $343 |
| Johnson & Johnson | 14 | $286 |
| GSK | 11 | $275 |
| Idorsia Pharmaceuticals US Inc | 13 | $270 |
| Amarin Pharma, Inc. | 11 | $199 |
| Pfizer | 10 | $198 |
| Baxter Healthcare | 4 | $171 |
| Heartflow, Inc. | 4 | $141 |
| Acella Pharmaceuticals, LLC | 5 | $94 |
| Genentech USA, Inc. | 4 | $85 |
| Alnylam Pharmaceuticals Inc. | 3 | $78 |
| Acerus Pharmaceuticals Corporation | 4 | $71 |
| Bayer | 3 | $66 |
| Currax Pharmaceuticals LLC | 4 | $64 |
| Azurity Pharmaceuticals, Inc. | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Galderma Laboratories, L.p. | 3 | $55 |
| G Medical Diagnostic Services, Inc. | 3 | $48 |
| Antares Pharma, Inc. | 2 | $47 |
| Scpharmaceuticals Inc. | 3 | $47 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Edwards Lifesciences | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Impulse Dynamics (USA) Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Abbott | 1 | $21 |
| United Therapeutics Corporation | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,935 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $80,561 |
| MounjaroTirzepatide | 60 | $65,105 |
| JardianceEmpagliflozin | 43 | $40,041 |
| XareltoRivaroxaban | 22 | $33,694 |
| EliquisApixaban | 22 | $18,611 |
| TradjentaLinagliptin | 19 | $14,102 |
| EntrestoSacubitril/Valsartan | 15 | $12,403 |
| NexletolBempedoic Acid | 16 | $6,499 |
| Liothyronine Sodium | 72 | $2,689 |
| Atorvastatin Calcium | 121 | $1,532 |
| Testosterone Cypionate | 27 | $1,042 |
| Levothyroxine Sodium | 123 | $997 |
| Rosuvastatin Calcium | 81 | $956 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 26 | $943 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,226 | $80,56173 claims |
| Lilly USA, LLCMounjaro | $868 | $65,10560 claims |
| Boehringer IngelheimJardiance, Tradjenta | $712 | $54,14362 claims |
| Johnson & JohnsonXarelto | $286 | $33,69422 claims |
| PfizerEliquis | $198 | $18,61122 claims |
| NovartisEntresto | $842 | $12,40315 claims |
| Esperion Therapeutics, Inc.Nexletol | $541 | $6,49916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Scarsdale
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
- Kelly WilmarthJohnson City$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.